Personalized medicine and treatment approaches in non-small-cell lung carcinoma

References

• SchillerJHHarringtonDBelaniCPComparison of four chemotherapy regimens for advanced non–small-cell lung cancerN Engl J Med20023462929811784875
   PubMed Web of Science ®Google Scholar
• KellyKCrowleyJBunnPARandomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trialJ Clin Oncol200119133210321811432888
   PubMed Web of Science ®Google Scholar
• HicklinDJEllisLMRole of the vascular endothelial growth factor pathway in tumor growth and angiogenesisJ Clin Oncol20052351011102715585754
   PubMed Web of Science ®Google Scholar
• FerraraNGerberHPLeCouterJThe biology of VEGF and its receptorsNat Med20039666967612778165
   PubMed Web of Science ®Google Scholar
• FerraraNHillanKJGerberH-PNovotnyWDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNat Rev Drug Discov20043539140015136787
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med2004350232335234215175435
   PubMed Web of Science ®Google Scholar
• GiantonioBJCatalanoPJMeropolNJBevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200J Clin Oncol200725121539154417442997
   PubMed Web of Science ®Google Scholar
• SaltzLBClarkeSDíaz-RubioEBevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III studyJ Clin Oncol200826122013201918421054
   PubMed Web of Science ®Google Scholar
• SaltzLBLenzH-JKindlerHLRandomized Phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 StudyJ Clin Oncol200725294557456117876013
   PubMed Web of Science ®Google Scholar
• MillerKWangMGralowJPaclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerN Engl J Med2007357262666267618160686
   PubMed Web of Science ®Google Scholar
• VredenburghJJDesjardinsAHerndonJEBevacizumab plus irinotecan in recurrent glioblastoma multiformeJ Clin Oncol200725304722472917947719
   PubMed Web of Science ®Google Scholar
• KreislTNKimLMooreKPhase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastomaJ Clin Oncol200927574074519114704
   PubMed Web of Science ®Google Scholar
• EscudierBPluzanskaAKoralewskiPBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trialLancet200737096052103211118156031
   PubMed Web of Science ®Google Scholar
• MargolinKGordonMSHolmgrenEPhase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety dataJ Clin Oncol200119385185611157039
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancerN Engl J Med2006355242542255017167137
   PubMed Web of Science ®Google Scholar
• HannaNShepherdFAFossellaFVRandomized Phase III trial of pemetrexed versus docetaxel in patients with non–small-cell lung cancer previously treated with chemotherapyJ Clin Oncol20042291589159715117980
   PubMed Web of Science ®Google Scholar
• PetersonPParkKFossellaFGatzemeierUJohnWScagliottiGIs pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): P2-328J Thorac Oncol200728S851
   Google Scholar
• SocinskiMABondarenkoINKarasevaNAResults of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC)ASCO Meeting Abstracts201028Suppl 18LBA7511
   Google Scholar
• SantosEMartin-ZancaDReddyEPierottiMDella PortaGBarbacidMMalignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patientScience198422346376616646695174
   PubMed Web of Science ®Google Scholar
• SuzukiYOritaMShiraishiMHayashiKSekiyaTDetection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction productsOncogene199057103710432197591
   PubMed Web of Science ®Google Scholar
• SchillerJHAdakSFeinsRHLack of prognostic significance of p53 and K-ras Mutations in primary resected non–small-cell lung cancer on E4592: a laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postoperative adjuvant therapyJ Clin Oncol200119244845711208838
   PubMed Web of Science ®Google Scholar
• MascauxCIanninoNMartinBThe role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysisBr J Cancer200592113113915597105
   PubMed Web of Science ®Google Scholar
• TsaoM-SAviel-RonenSDingKPrognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non–small-cell lung cancerJ Clin Oncol200725335240524718024870
   PubMed Web of Science ®Google Scholar
• BruggerWTrillerNBlasinska-MorawiecMProspective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancerJ Clin Oncol201129314113412021969500
   PubMed Web of Science ®Google Scholar
• JackmanDMYeapBYLindemanNIPhase II Clinical Trial of chemotherapy-naïve patients ≥70 years of age treated with erlotinib for advanced non–small-cell lung cancerJ Clin Oncol200725776076617228019
   PubMed Web of Science ®Google Scholar
• MillerVARielyGJZakowskiMFMolecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinibJ Clin Oncol20082691472147818349398
   PubMed Web of Science ®Google Scholar
• MassarelliEVarella-GarciaMTangXKRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancerClin Cancer Res200713102890289617504988
   PubMed Web of Science ®Google Scholar
• PaoWWangTYRielyGJKRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinibPLoS Med2005215761
   Web of Science ®Google Scholar
• BrunnerTBHahnSMGuptaAKMuschelRJMcKennaWGBernhardEJFarnesyltransferase InhibitorsCancer Res200363185656566814522880
   PubMed Web of Science ®Google Scholar
• AppelsNMGMBeijnenJHSchellensJHMDevelopment of farnesyl transferase inhibitors: a reviewOncologist200510856557816177281
   PubMed Web of Science ®Google Scholar
• RielyGJJohnsonMLMedinaCA Phase II trial of salirasib in patients with lung adenocarcinomas with KRAS mutationsJ Thorac Oncol2011681435143721847063
   PubMed Web of Science ®Google Scholar
• OdaKMatsuokaYFunahashiAKitanoHA comprehensive pathway map of epidermal growth factor receptor signalingMol Syst Biol200512005.001016729045
   PubMed Web of Science ®Google Scholar
• ShepherdFARodrigues PereiraJCiuleanuTErlotinib in previously treated non–small-cell lung cancerN Engl J Med2005353212313216014882
   PubMed Web of Science ®Google Scholar
• GiacconeGGallegos RuizMLe ChevalierTErlotinib for frontline treatment of advanced non–small cell lung cancer: a Phase II studyClin Cancer Res200612206049605517062680
   PubMed Web of Science ®Google Scholar
• CappuzzoFCiuleanuTStelmakhLErlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 studyLancet Oncol201011652152920493771
   PubMed Web of Science ®Google Scholar
• LeeDKimS-WSuhCHanYLeeJ-SPhase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doubletsCancer Chemother Pharmacol2011671353920182725
   PubMed Web of Science ®Google Scholar
• HidalgoMSiuLLNemunaitisJPhase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignanciesJ Clin Oncol200119133267327911432895
   PubMed Web of Science ®Google Scholar
• BaselgaJRischinDRansonMPhase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor typesJ Clin Oncol200220214292430212409327
   PubMed Web of Science ®Google Scholar
• FukuokaMYanoSGiacconeGMulti-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancerJ Clin Oncol200321122237224612748244
   PubMed Web of Science ®Google Scholar
• ThatcherNChangAParikhPGefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Lancet200536694961527153716257339
   PubMed Web of Science ®Google Scholar
• NihoSKubotaKGotoKFirst-line single agent treatment with gefitinib in patients with advanced non–small-cell lung cancer: a Phase II studyJ Clin Oncol2006241646916382114
   PubMed Web of Science ®Google Scholar
• ZhangLShenglinMSongXEfficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC; INFORM; C-TONG 0804)J Clin Oncol201129Suppl Abstr LBA7511
   Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinibN Engl J Med2004350212129213915118073
   PubMed Web of Science ®Google Scholar
• PaezJGJännePALeeJCEGFR Mutations in lung cancer: correlation with clinical response to gefitinib therapyScience200430456761497150015118125
   PubMed Web of Science ®Google Scholar
• SharmaSVBellDWSettlemanJHaberDAEpidermal growth factor receptor mutations in lung cancerNat Rev Cancer20077316918117318210
   PubMed Web of Science ®Google Scholar
• HerbstRSPragerDHermannRTRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non–small-cell lung cancerJ Clin Oncol200523255892589916043829
   PubMed Web of Science ®Google Scholar
• GatzemeierUPluzanskaASzczesnaAPhase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non–small-cell lung cancer: the Tarceva Lung Cancer Investigation TrialJ Clin Oncol200725121545155217442998
   PubMed Web of Science ®Google Scholar
• GiacconeGHerbstRSManegoldCGefitinib in combination with gemcitabine and cisplatin in advanced non–small-cell lung cancer: a Phase III trial – INTACT 1J Clin Oncol200422577778414990632
   PubMed Web of Science ®Google Scholar
• HerbstRSGiacconeGSchillerJHGefitinib in combination with paclitaxel and carboplatin in advanced non–small-cell lung cancer: a Phase III trial – INTACT 2J Clin Oncol200422578579414990633
   PubMed Web of Science ®Google Scholar
• MokTSWuY-LThongprasertSGefitinib or carboplatin–paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
   PubMed Web of Science ®Google Scholar
• MaemondoMInoueAKobayashiKGefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFRN Engl J Med2010362252380238820573926
   PubMed Web of Science ®Google Scholar
• ZhouCWuY-LChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol201112873574221783417
   PubMed Web of Science ®Google Scholar
• RosellRGervaisRVergnenegreAErlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trialJ Clin Oncol201129Suppl Abstr 7503
   Google Scholar
• MitsudomiTMoritaSYatabeYGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
   PubMed Web of Science ®Google Scholar
• DufortSRichardM-JLantuejoulSde FraipontFPyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLCJ Exp Clin Cancer Res20113015721575212
   PubMed Web of Science ®Google Scholar
• NomotoKTsutaKTakanoTDetection of EGFR mutations in archived cytologic specimens of non–small cell lung cancer using high-resolution melting analysisAm J Clin Pathol2006126460861516938658
   PubMed Web of Science ®Google Scholar
• HanH-SLimS-nAnJYDetection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivityJ Thorac Oncol20127235536422157369
   PubMed Web of Science ®Google Scholar
• AsanoHToyookaSTokumoMDetection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assayClin Cancer Res2006121434816397022
   PubMed Web of Science ®Google Scholar
• NaokiKSoejimaKOkamotoHThe PCR-invader method (structure-specific 5′ nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencingInt J Clin Oncol201116433534421311943
   PubMed Web of Science ®Google Scholar
• SequistLVHeistRSShawATImplementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practiceAnn Oncol201122122616262422071650
   PubMed Web of Science ®Google Scholar
• PirkerRHerthFJFKerrKMConsensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshopJ Thorac Oncol20105101706171320871269
   PubMedGoogle Scholar
• GreulichHChenTHFengWOncogenic transformation by inhibitor-sensitive and -resistant EGFR mutantsPLoS Med2005211e31316187797
   PubMed Web of Science ®Google Scholar
• KobayashiSBoggonTJDayaramTEGFR mutation and resistance of non–small-cell lung cancer to gefitinibN Engl J Med2005352878679215728811
   PubMed Web of Science ®Google Scholar
• BeanJRielyGJBalakMAcquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinomaClin Cancer Res200814227519752519010870
   PubMed Web of Science ®Google Scholar
• YangC-HShihJ-YSuW-CA phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR/HER1 mutations (LUX-LUNG 2)ESMO5192010 Abstract 4132
   Google Scholar
• ShihJ-YYuC-JSuW-CActivity of BIBW 2992, an irreversible EGFR/HER1 and HER2 TKI, in lung adenocarcinoma patients harboring less common EGFR mutationsESMO5192010 Abstract 4162
   Google Scholar
• MillerVHirshVCadranelJPhase IIB/III double-blind randomized trial of afatinib (BIBW 2992, an irreversible inhibitor of the EGFR/HER1 and HER2) + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1–2 lines of chemotherapy and erlotinib or gefitinib (LUX-LUNG 1)ESMO5192010 Abstract LBA1
   Google Scholar
• YamamotoNKatakamiNAtagiSA phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G)J Clin Oncol201129Suppl Abstract 7524
   Google Scholar
• JanjigianYYGroenHJHornLActivity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinibJ Clin Oncol.201129Suppl Abstract 7525
   Google Scholar
• MokTSpigelDRParkKEfficacy and safety of PF299804 as first-line treatment of patients with advanced NSCLC selected for activating mutation of epidermal growth factor receptor (EGFR)ESMO5192010 Abstract LBA18
   Google Scholar
• RamalingamSSBoyerMJParkKRandomized phase 2 study of PF299804, an irreversible human epidermal growth factor receptor (EGFR) inhibitor, versus erlotinib in patients with advanced non-small cell lung cancer after chemotherapy failure: quantitative and qualitative benefitsESMO5192010 Abstract 3778
   Google Scholar
• BoyerMJBlackhallFHParkKEfficacy and safety of PF299804 versus erlotinib (E): a global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT)J Clin Oncol201028Suppl 18 Abstract LBA7523
   Web of Science ®Google Scholar
• ParkKHeoDSChoBPF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): a phase (P) I/II studyJ Clin Oncol201028Suppl 15 Abstract 7599
   Web of Science ®Google Scholar
• EngelmanJAZejnullahuKMitsudomiTMET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingScience200731658271039104317463250
   PubMed Web of Science ®Google Scholar
• BeanJBrennanCShihJ-YMET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProc Natl Acad Sci U S A200710452209322093718093943
   PubMed Web of Science ®Google Scholar
• SpigelDRErvinTJRamlauRFinal efficacy results from OAM4558 g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLCJ Clin Oncol201129Suppl 15 Abstract 7505
   Web of Science ®Google Scholar
• SequistLVvon PawelJGarmeyEGRandomized Phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non–small-cell lung cancerJ Clin Oncol201129243307331521768463
   PubMed Web of Science ®Google Scholar
• Al-SaleemTAl-MondhiryHImmunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasmsBlood200510562274228015542584
   PubMed Web of Science ®Google Scholar
• McNeelySContiCSheikhTChk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinaseCell Cycle201095995100420160494
   PubMed Web of Science ®Google Scholar
• OlaussenKADunantAFouretPDNA repair by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemotherapyN Engl J Med20063551098399116957145
   PubMed Web of Science ®Google Scholar
• SodaMChoiYLEnomotoMIdentification of the transforming EML4-ALK fusion gene in non-small-cell lung cancerNature2007448715356156617625570
   PubMed Web of Science ®Google Scholar
• KwakELCamidgeDRClarkJClinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066J Clin Oncol200927Suppl 15 Abstract 3509
   Web of Science ®Google Scholar
• KwakELBangY-JCamidgeDRAnaplastic lymphoma kinase inhibition in non–small-cell lung cancerN Engl J Med2010363181693170320979469
   PubMed Web of Science ®Google Scholar
• CamidgeDRBangYKwakELProgression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC)J Clin Oncol201129Suppl 15 Abstract 2501
   Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA labeling information – Crizotinib/Xalkori2011
   Google Scholar
• YiESBolandJMMaleszewskiJJCorrelation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISHJ Thorac Oncol20116345946521278610
   PubMed Web of Science ®Google Scholar
• PaikJHChoeGKimHScreening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridizationJ Thorac Oncol20116346647221258247
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA approves Xalkori with companion diagnostic for a type of late-stage lung cancer8262011 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269856.htm. Accessed May 14, 2011
   Google Scholar
• HirschFRVarella-GarciaMBunnPAEpidermal growth factor receptor in non–small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosisJ Clin Oncol200321203798380712953099
   PubMed Web of Science ®Google Scholar
• PirkerRPereiraJRSzczesnaACetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialLancet200937396741525153119410716
   PubMed Web of Science ®Google Scholar
• LynchTJPatelTDreisbachLCetuximab and first-line taxane/carboplatin chemotherapy in advanced non–small-cell lung cancer: results of the randomized multicenter Phase III trial BMS099J Clin Oncol201028691191720100966
   PubMed Web of Science ®Google Scholar
• PirkerRPereiraJRvon PawelJEGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX studyLancet Oncol2012131334222056021
   PubMed Web of Science ®Google Scholar